Updates on the Treatment of Pterygium

Todorović, Dušan; Vulović, Tatjana Šarenac; Srećković, Sunčica; Jovanović, Svetlana; Janićijević, Katarina; Todorović, Zoran

doi:10.1515/sjecr-2016-0012

Cited by 4 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High recurrence rates associated with postsurgical complications continue to be a problem; thus, adjunctive medical management has been incorporated into pterygium's surgical treatment. The adjunctive therapy in pterygium management includes the administration of mitomycin C, anti-VEGF, 5-fluorouracil (5-FU), and loteprednol etabonate [47].…”

Section: B Adjuvant Therapiesmentioning

confidence: 99%

“…Nevertheless, the use of MMC carries a risk of complications of causing chronic keratopathy and toxic keratoconjunctivitis. Therefore, intraoperative use is recommended so that the dosage of this drug can be more easily controlled [47].…”

Section: B Adjuvant Therapiesmentioning

confidence: 99%

“…The uniqueness of this regimen lies in its structure, which can penetrate the cell membrane thoroughly and is rapidly converted to inactive metabolites, thereby reducing the risk of side effects of steroid use on the eye, such as increased intraocular pressure and cataract formation. Thus, this regimen can be a potential in future pterygium therapy [47]. Another study demonstrated a reduction in recurrence rate by 50% by using lubricant eye drops after steroid instillation for a post-surgery period of three months [59].…”

Section: B Adjuvant Therapiesmentioning

confidence: 99%

See 2 more Smart Citations

Updates on the Mechanism and Management of Pterygium: A Brief Review

Sakti¹

2021

EJMED

View full text Add to dashboard Cite

Pterygium is an ocular surface disease characterized by invasive fibrovascular growth due to pathological proliferation and inflammation on the conjunctival and corneal tissue. Its occurrence has been associated with chronic ultraviolet exposure, thus becoming one of the most common eye problems in tropical regions worldwide. Although pterygium rarely causes severe visual disturbances or blindness, it often becomes a distressing problem because of the high recurrence rate and unsatisfactory cosmetic outcomes, despite receiving removal management. In recent decades, studies regarding molecular mechanisms and management of pterygium have been advanced. This review provides a brief update on the mechanism and management to achieve more optimal and satisfactory pterygium therapeutic approaches.

show abstract

Section: B Adjuvant Therapiesmentioning

confidence: 99%

Section: B Adjuvant Therapiesmentioning

confidence: 99%

Section: B Adjuvant Therapiesmentioning

confidence: 99%

See 1 more Smart Citation

Updates on the Mechanism and Management of Pterygium: A Brief Review

Sakti¹

2021

EJMED

View full text Add to dashboard Cite

show abstract

“…Increased AGE immune reactivity provokes collagen crosslinking with stromal alterations (36). Accumulated ROS with increased levels of some growth factors activate proliferation and activation of keratocytes in posterior stroma in young diabetic patients (6) (37) (38).…”

Section: Stromal Changes In Dkmentioning

confidence: 99%

The Corneal Changes in Diabetic Patients

Srećković

Todorović

Stojanovic

2021

Serbian Journal of Experimental and Clinical Research

Self Cite

View full text Add to dashboard Cite

Diabetes mellitus (DM) represents a systemic disorder which afects different organs. Ocular complications of the DM are the worldwide leading cause of blindness. The most common complications are diabetic retinopathy, diabetic cataract, neovascular glaucoma. Recently many investigations point out that DM can cause comlications at ocular surface as well. Condition such as decreased corneal sensitivity, dry eye or neurotrophic corneal ulceraction are the main clinical manifestations of the diabetic keratopathy (DK). Untreated, these conditions can lead to serious visual acuity decrease. Pathological processes, based on chronic inflammation, due to chronic hyperglycemia, are the main step in the process of DK development. Adequate treatment of the main disease - DM is an imperative in maintaining the healthy cornea without subjective sensations of diabetic patients.

show abstract